The merger is a binary event for PULM holders. The stock will likely trade on the probability of deal closure and the perceived value of Eos's preclinical pipeline. Monitor the special meeting vote on October 2 and any updates on Eos's $13M+ financing condition. Post-merger, the combined company's stock (MTXL) will be a high-risk, pre-revenue biotech play focused on gerotherapeutics.
Price Chart
Executive Summary
Pulmatrix filed Amendment No. 2 to its S-4 registration statement, advancing the proposed reverse merger with Eos SENOLYTIX. The filing sets a special stockholder meeting for October 2, 2026, to vote on key proposals including share issuance for the merger (which would dilute current PULM holders to ~6% of the combined company), a reverse stock split, and an authorized share increase. The merger is a transformative event that will effectively transfer control to Eos, with the combined company to be renamed Eos SENOLYTIX Inc. and trade under 'MTXL', but existing PULM holders face massive dilution and the combined entity is a pre-revenue biotech with significant execution risk.
Key Facts
- Pulmatrix stockholders will own approximately 6% of the combined company post-merger, with Eos securityholders owning ~94%.
- The special meeting is scheduled for October 2, 2026, to vote on the merger, reverse stock split (1:2 to 1:10), and authorized share increase from 200M to 250M shares.
- Eos must receive at least $13M in gross cash proceeds from financing transactions as a condition to closing.
- The combined company will be a 'controlled company' with SENOTHERAPEUTIX, Inc. expected to own >50% voting power.
- Pulmatrix reported a net loss of $5.2M in 2025 and had $2.2M cash as of June 30, 2026, with substantial doubt about its ability to continue as a going concern without the merger.
Financial Impact
Current PULM holders diluted to ~6% of combined entity; implied value of Pulmatrix's 6% interest is ~$7.85M based on a $100M pre-money valuation for Eos plus $19M in capital. Pulmatrix had $2.2M cash as of June 30, 2026.
Risk Factors
- Massive dilution: current PULM holders will own only ~6% of the combined company.
- Merger may not close if stockholder votes or financing conditions are not met; Pulmatrix has going-concern risk without the deal.
- Combined company is pre-revenue with preclinical assets (PTC-2105) facing high clinical development risk.
- Controlled company structure gives SENOTHERAPEUTIX majority voting power, limiting minority shareholder influence.
- Nasdaq listing of combined company (MTXL) is conditional on meeting initial listing standards, including a $4.00 bid price after reverse split.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (PULM) — Batch item 1 | 0001493152-26-041607 |
| Exhibit: ex4-7.htm | 0001493152-26-041607 |
| Exhibit: ex5-1.htm | 0001493152-26-041607 |
| Exhibit: ex99-5.htm | 0001493152-26-041607 |
| Exhibit: ex99-6.htm | 0001493152-26-041607 |
| Exhibit: ex23-1.htm | 0001493152-26-041607 |
| Exhibit: ex23-3.htm | 0001493152-26-041607 |
| Exhibit: ex23-2.htm | 0001493152-26-041607 |
| Document: 0001493152-26-041607-index-headers.html | 0001493152-26-041607 |
| Document: 0001493152-26-041607-index.html | 0001493152-26-041607 |
| Document: 0001493152-26-041607.txt | 0001493152-26-041607 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | S-4/A | $1.40 $1.45 | ▼ −3.58% | ▼ −4.70% | $1.57 (−12.54%) |
Aug 13, 2026 7w ago | 8-K | $1.51 $1.50 | ▼ −0.66% | ▲ +1.30% | $1.57 (+3.97%) |
Aug 13, 2026 7w ago | Press Release | $1.51 $1.50 | ▲ +0.66% | ▼ −1.30% | $1.57 (−3.97%) |
Aug 7, 2026 7w ago | S-3/A | $1.57 $1.56 | ▲ +0.64% | ▲ +0.59% | $1.57 (−0.00%) |
Jun 16, 2026 15w ago | 10-K/A | $1.50 $1.53 | ▲ +2.00% | ▲ +3.04% | $1.57 (+4.67%) |
Jun 5, 2026 17w ago | 425 | $1.33 $1.40 | ▲ +5.26% | ▲ +4.69% | $1.57 (+18.05%) |
Jun 4, 2026 17w ago | S-3 | $1.32 $1.38 | ▼ −4.55% | ▼ −7.10% | $1.57 (−18.94%) |
May 15, 2026 20w ago | 8-K | $1.25 $1.34 | ▲ +7.20% | ▲ +6.24% | $1.57 (+25.60%) |
Apr 21, 2026 23w ago | 8-K | $1.38 $1.28 | ▼ −7.25% | ▼ −8.33% | $1.57 (+13.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access